Oncology for the Inquisitive Mind

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz
Country USA
Language EN
Episodes 237
Latest 17.11.2026

Oncology for the Inquisitive Mind is a medical podcast hosted by Dr Michael Fernando and Dr Joshua Hurwitz that helps listeners keep pace with a fast-moving field. Each episode covers the latest clinical trials, research findings and practice-changing updates in cancer care. The hosts also interview renowned oncology specialists on a regular basis. It is aimed at trainees just starting out, established specialists and anyone drawn to medical science, with some bad jokes along the way.

Episodes

  • 221. Making Metastatic Breast Cancer Count with Vicki Durston
    221. Making Metastatic Breast Cancer Count with Vicki Durston 17.11.2026 33m
    How many Australians are living with metastatic breast cancer? Until recently, nobody could tell you.This episode we’re joined by Vicki Durston, Director of Policy and Advocacy at Breast Cancer Network Australia (BCNA). Vicki started out as a nurse and has spent more than 30 years in health leadership. Her team produced Australia’s first national estimate of people living with metastatic breast cancer.BCNA is the peak national organisation for Australians affected by breast cancer. It began in 1998 with a few hundred women sharing information in their living rooms. It’s now a network of more t...
  • 220. Back to Basics - Central Nervous System Tumours
    220. Back to Basics - Central Nervous System Tumours 08.11.2026 28m
    This episode is about IDH-mutant glioma, a cancer that often hits people in their thirties and forties who may live for decades, which makes the long-term cost of treatment matter as much as the benefit. We’re looking at two trials, almost thirty years apart. RTOG 9402 opened in 1994 and asked whether adding PCV chemotherapy to radiotherapy did better than radiotherapy alone in anaplastic oligodendroglioma. INDIGO asked whether a daily tablet, the IDH inhibitor vorasidenib, could let patients with grade 2 disease put off radiotherapy and chemotherapy altogether. One asks whether more is better...
  • 219. Back to Basics - Cervical Cancer
    219. Back to Basics - Cervical Cancer 03.11.2026 23m
    Cervical cancer is notoriously difficult to treat, but treatment like most cancers continue to improve. This week we discuss two pivotal immunotherapy (Keynote) trials.KEYNOTE-826 was the first trial to show that adding immunotherapy to first-line chemotherapy helps women whose cervical cancer has come back or spread. They lived longer, and five-year results confirm the benefit lasts. KEYNOTE-A18 then moved pembrolizumab earlier, adding it to chemoradiation for newly diagnosed, high-risk disease, when the aim is cure. At three years, 82.6% of women were alive, compared with 74.8% with chemorad...
  • 218. Back to Basics - Endometrial Cancer
    218. Back to Basics - Endometrial Cancer 24.10.2026 28m
    This week we cover endometrial cancer. It is one of the clearest examples of molecular classification changing how we treat patients. PORTEC-3 randomised women with high-risk disease to pelvic radiotherapy with or without chemotherapy. Adding chemotherapy improved survival, and the benefit held at 10 years. The molecular analysis is where it gets interesting, but you'll have to tune in to find out why! RUBY then showed those same dMMR tumours respond to something else entirely. Adding dostarlimab to carboplatin-paclitaxel in advanced or recurrent disease improved overall survival. Should one m...
  • 217. Back to Basics - Advanced Ovarian Cancer
    217. Back to Basics - Advanced Ovarian Cancer 17.10.2026 25m
    Last week Josh and Michael discussed early ovarian cancer, but as is always the case many patients either do not respond completely to treatment of their early disease or present with advanced disease and thus are robbed of that chance. In these patients, getting the treatment right is a complex discussion but a vital one. In this episode, we discuss two studies in the advanced ovarian cancer space, a space that could still use more love, but has seen developments in recent years. Studies Discussed in Today's EpisodeAURELIAICON4For more episodes, resources and blog posts, visit www.inquisitive...
  • 216. Back to Basics - Early Ovarian Cancer
    216. Back to Basics - Early Ovarian Cancer 10.10.2026 21m
    Our Back to Basics odyssey nears its end, a journey just as epic as Matt Damon's (we think so, anyway). As we enter the final stretch, we discuss ovarian cancer, a cancer with significant mortality and morbidity despite advances in treatment. In this episode Josh and Michael discuss two studies in the early ovarian cancer space, a topic fraught with challenges as unique as Scylla and Charybdis.Studies Discussed in Today's EpisodeICON7PAOLA-1For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific tri...
  • 215. Back to Basics - Advanced Melanoma
    215. Back to Basics - Advanced Melanoma 20.09.2026 27m
    On this episode, Josh and Michael examine the treatment of advanced melanoma, the condition that blazed the trail for immunotherapy to change the face of cancer treatment. However, immunotherapy is not the ONLY treatment for melanoma, as a significant proportion of cases also harbour a BRAF mutation. So, if you have someone with such an example, what do you do? How would you sequence your treatment? This question, and a reflection on the incredible beginnings of immunotherapy is coming to you on today's episode.Studies Discussed in Today's EpisodeCheckmate 067DreamSeqFor more episodes, resourc...
  • 214. Dr Narjust Florez and the rise of early onset lung cancer
    214. Dr Narjust Florez and the rise of early onset lung cancer 12.09.2026 34m
    Our guest today is someone whose work touches almost every corner of oncology: from the exam room to the lab to the systems we work within.Dr Narjust Florez, MD, FASCO, is a thoracic medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, where she treats young patients and women with lung cancer and leads a research program spanning early diagnosis, clinical trials, and cancer health disparities. She's the Associate Director of the Cancer Care Equity Program and leads the EQUAL Study, which tackles disparities in lung cancer screening...
  • 213. Back to Basics - Early Melanoma
    213. Back to Basics - Early Melanoma 07.09.2026 28m
    In this episode, Michael and Josh delve into the world of early melanoma. Some may think that melanoma has had its moment in the sun (pun slightly intended) and that other cancer treatments are passing it by. But in this instance, you can teach an old dog new tricks, an old immunotherapy dog, to be precise. In addition, one of today's studies has Michael's favourite design of any trial: see if you can figure out which one!Studies Discussed in Today's EpisodeKEYNOTE-054NADINAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you...
  • 212. Back to Basics - Non-Melanoma Skin Cancer
    212. Back to Basics - Non-Melanoma Skin Cancer 29.08.2026 24m
    If you like cemiplimab, you will like this episode. Since its introduction, cemiplimab has become the mainstay of treatment for cutaneous SCC, the most common non-melanoma skin cancer likely to attend an oncologist. Cemiplimab's scope is expanding; once reserved purely for the locally advanced or metastatic setting, evidence is emerging for its efficacy in the neoadjuvant setting. Today, Josh and Michael explore the use cases for cemiplimab in cSCCNOTE: this episode was NOT sponsored by cemiplimab!Studies Discussed in Today's EpisodeMigden et al. (2018)Gross et al (2023)For more episodes, reso...
  • 211. Back to Basics - Hepatocellular Carcinoma
    211. Back to Basics - Hepatocellular Carcinoma 22.08.2026 26m
    For over a decade, sorafenib remained unchallenged as first-line therapy for hepatocellular carcinoma, based on the SHARP trial, which showed survival increasing from 7.9 to 10.7 months. This demonstrated modest efficacy in a disease notoriously resistant to systemic treatment. That drought broke in 2020, when IMbrave150 demonstrated that atezolizumab plus bevacizumab beat sorafenib outright, pushing median survival past 19 months and putting immunotherapy on the map for liver cancer. Two years later, HIMALAYA proved that a single priming dose of anti-CTLA-4 could unlock durable responses, wit...
  • 210. Back to Basics - Biliary Tract Cancers
    210. Back to Basics - Biliary Tract Cancers 15.08.2026 22m
    Until recently, biliary tract cancers were relegated to orphan cancer status: rare cancers such as cholangiocarcinoma and gallbladder cancers. These aggressive malignancies were lumped together, historic trials were small, and patients were stuck with gemcitabine-cisplatin chemotherapy as the only real option, a regimen that hadn't changed for almost a decade. Then two trials cracked the field open. BILCAP, reported in 2019, gave resected patients their first evidence-based reason to take adjuvant capecitabine, pushing median survival from around three years to over four. And in 2022, TOPAZ-1...
  • 209. Interview with Dr Kerry Jewell
    209. Interview with Dr Kerry Jewell 08.08.2026 1h 7m
    On today's episode, we have a very special guest: Dr Kerry Jewell is a nuclear medicine physician, medical advocate and very good friend of the show, who recently published her debut novel A Little Unwell. Kerry is wonderfully eloquent doctor who frequently chooses violence when with dealing with Michael, whom she has known for his entire medical career. Today, Kerry discusses her book, working as a nuclear medicine physician, provides some of her amazing wisdom for our oncology colleagues and gets candid about a recent, heart-breaking diagnosis. A Little Unwell available here: https://www.ama...
  • 208. ASCO 2026 - The Plenary Episode - Part 3
    208. ASCO 2026 - The Plenary Episode - Part 3 12.07.2026 52m
    This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expectancy and quality of life need their time in the spotlight.Today, five trials are discussed, including SARC041, a liposarcoma study utilising the CDK 4/6 inhibigtor abemacicilib. Our second study is HARMONI-6, investigating whether ivonescimab plus chemotherapy is effective in patients with advanced squamous non-small...
  • 207. ASCO 2026 - Agents of the Future - Part 2
    207. ASCO 2026 - Agents of the Future - Part 2 05.07.2026 1h 4m
    This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and neck cancer, basket cohort studies, resistant EGFR lung cancer, metastatic colorectal cancer and hepatocellular carcinoma.One more episode left of this arc - The Plenary! Stay tuned.Studies Discussed in this EpisodeOrigAMI-4WU-KONG28A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic CancerESANOAROS...
  • 206. ASCO 2026 - Part 1
    206. ASCO 2026 - Part 1 28.06.2026 1h 1m
    ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-free survival data that could influence your practice.They cover immunotherapy, lifestyle interventions, pan-PI3K inhibitors, rare cancers (such as uveal melanoma), and antibody drug conjugates, to name a few. All the cancer types are covered, including genitourinary, gynaecological cancers, breast, colorectal, lung and lifestyle interventions!Two more episodes to come!Studies...
  • 205. ESTRO update with A/Prof Steven David
    205. ESTRO update with A/Prof Steven David 14.06.2026 22m
    This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveo...
  • 204. Jake Messier on Living with Metastatic Male Breast Cancer
    204. Jake Messier on Living with Metastatic Male Breast Cancer 07.06.2026 43m
    This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an important reminder that not all cancers are funded and researched equally, and that behind every statistic is a person trying to live a normal life.Jake has used his lifelong PR skills to turn what is a diagnosis unlike any other into a conversation about equity, resilience and a deep societal stigma. This conversation should also serve as a reminder of how patients perceive the h...
  • 203. Back to Basics - Early Pancreatic Cancer
    203. Back to Basics - Early Pancreatic Cancer 31.05.2026 25m
    This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy in pancreatic cancer, and Josh does a traditional deep dive into the world of neoadjuvant chemotherapy. He highlights ESPAC-5, PREOPANC-2, and the TAPS consortium, to name a few. A complicated but overall evolving field.Studies discussed in this episode:ESPAC-4FOLFOXIRIPREOPANC-2ESPAC-5TAPS (Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Study)For more episodes, resources a...
  • 202. Back to Basics - Advanced Pancreatic Cancer
    202. Back to Basics - Advanced Pancreatic Cancer 24.05.2026 22m
    Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. While small incremental advances have been made, the holy grail remains elusive.Today our focus is on NAPOLI-3, the use of liposomal irinotecan (NALIRIFOX), and PANOVA-3, where TTFields are used in combination with gemcitabine/abraxane. A good conversation, though the current premise is sad. Hopefully, as time moves on, this conversation will be more optimistic. Studies discussed...

Popular in

The podcast also appears in the podcast charts of these countries.